4.7 Article

Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy A Pooled Cohort Analysis

期刊

HYPERTENSION
卷 77, 期 4, 页码 1106-1118

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/HYPERTENSIONAHA.120.16689

关键词

blood pressure; calcium; cardiovascular disease; coronary heart disease; heart failure; risk; stroke

资金

  1. National Institutes of Health Mentored Patient-Oriented Research Award [5K23HL146887-02]

向作者/读者索取更多资源

The study evaluated the use of coronary artery calcium (CAC) score to guide hypertension therapy in individuals without cardiovascular disease. Results showed that among those with CAC>0, there was a higher risk of incident cardiovascular events in individuals with elevated BP or low-risk stage 1 hypertension, as well as in those with high-risk stage 1 or stage 2 hypertension. The study suggests that utilizing CAC score may help personalize cardiovascular risk reduction strategies in individuals where current guidelines do not recommend treatment.
The 2017 American College of Cardiology/American Heart Association high blood pressure (BP) guidelines recommend risk assessment of atherosclerotic cardiovascular disease to inform hypertension treatment in adults with elevated BP or low-risk stage I hypertension. The use of coronary artery calcium (CAC) score to guide hypertension therapy has not been adequately evaluated. Participants free of cardiovascular disease were pooled from Multi-Ethnic Study of Atherosclerosis, Coronary Artery Risk Development in Young Adults, and Jackson Heart Study. The risk for incident cardiovascular events (heart failure, stroke, coronary heart disease), by CAC status (CAC-0 or CAC>0) and BP treatment group was assessed using multivariable-adjusted Cox regression. The 10-year number needed to treat to prevent a single cardiovascular event was also estimated. This study included 6461 participants (median age 53 years; 53.3% women; 32.3% Black participants). Over a median follow-up of 8.5 years, 347 incident cardiovascular events occurred. Compared with those with normal BP, the risk of incident cardiovascular event was higher among those with elevated BP/low-risk stage I hypertension and CAC>0 (hazard ratio, 2.4 [95% CI, 1.7-3.4]) and high-risk stage I/stage II hypertension (BP, 140-160/80-100 mm Hg) with CAC>0 (hazard ratio, 2.9 [95% CI, 2.1-4.0]). A similar pattern was evident across racial subgroups and for individual study outcomes. Among those with CAC-0, the 10-year number needed to treat was 160 for elevated BP/low-risk stage I hypertension and 44 for high-risk stage I or stage II hypertension (BP, 140-160/80-100 mm Hg). Among those with CAC>0, the 10-year number needed to treat was 36 and 22, respectively. Utilization of the CAC score may guide the initiation of hypertension therapy and preventive approaches to personalize cardiovascular risk reduction among individuals where the current guidelines do not recommend treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据